A Phase I, Randomized, Double-Blind Clinical Trial of the HIV gp120/NefTat/AS02A Vaccine Candidate in Subjects With Well-Controlled Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART).

Trial Profile

A Phase I, Randomized, Double-Blind Clinical Trial of the HIV gp120/NefTat/AS02A Vaccine Candidate in Subjects With Well-Controlled Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART).

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Sep 2011

At a glance

  • Drugs AS02; HIV vaccine
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Feb 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
    • 24 Mar 2009 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top